Literature DB >> 20515774

Regulation of p53 isoform expression in renal cell carcinoma.

Linda van den Berg1, Adebowale Daniel Segun, Sabrina Mersch, Nina Blasberg, Edgar Grinstein, Daniel Wai, Martin Anlauf, Helmut Erich Gabbert, Csaba Mahotka, Sebastian Heikaus.   

Abstract

Differential expression of p53 isoforms might participate in the marked resistance towards conventional chemotherapy of renal cell carcinomas (RCCs). Therefore, we analysed their differential expression and regulation in RCCs. RCCs expressed a more p53 activating isoform pattern during tumor initiation and progression, in vivo. In vitro, two cell lines exhibiting a similar sensitivity towards Topotecan-induced cell death revealed a similar induction of p53 target genes but strongly differed in their extent of apoptosis. Furthermore, they strongly differed in their basal expression patterns and differential regulation of the isoforms. In conclusion, our study examined for the first time the differential expression and regulation of all p53 isoforms in a tumor in vivo. Furthermore, novel results in our in vitro studies show that p53 isoforms are strongly differentially regulated by chemotherapy in RCCs and that expression and regulation of so-called "p53-target genes" are obviously at least in part regulated by other transcription factors. In addition, our original findings show that p53 isoform expression in RCC cell lines is of minor importance for sensitivity towards chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20515774     DOI: 10.2741/e162

Source DB:  PubMed          Journal:  Front Biosci (Elite Ed)        ISSN: 1945-0494


  7 in total

1.  The role of apoptosis repressor with a CARD domain (ARC) in the therapeutic resistance of renal cell carcinoma (RCC): the crucial role of ARC in the inhibition of extrinsic and intrinsic apoptotic signalling.

Authors:  Csaba Toth; Sarah Funke; Vanessa Nitsche; Anna Liverts; Viktoriya Zlachevska; Marcia Gasis; Constanze Wiek; Helmut Hanenberg; Csaba Mahotka; Peter Schirmacher; Sebastian Heikaus
Journal:  Cell Commun Signal       Date:  2017-05-02       Impact factor: 5.712

Review 2.  p53 and Its Isoforms in Renal Cell Carcinoma-Do They Matter?

Authors:  Agata Swiatkowska
Journal:  Biomedicines       Date:  2022-06-06

Review 3.  p53 Proteoforms and Intrinsic Disorder: An Illustration of the Protein Structure-Function Continuum Concept.

Authors:  Vladimir N Uversky
Journal:  Int J Mol Sci       Date:  2016-11-10       Impact factor: 5.923

4.  Role of Δ133p53 isoform in NF-κB inhibitor PDTC-mediated growth inhibition of MKN45 gastric cancer cells.

Authors:  Hong-Mei Zhang; Xiao-Guang Sang; Yan-Ze Wang; Can Cui; Li Zhang; Wan-Sheng Ji
Journal:  World J Gastroenterol       Date:  2017-04-21       Impact factor: 5.742

5.  VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.

Authors:  Caroline Fanja Razafinjatovo; Daniel Stiehl; Eva Deininger; Markus Rechsteiner; Holger Moch; Peter Schraml
Journal:  Oncotarget       Date:  2017-02-07

6.  p73 coordinates with Δ133p53 to promote DNA double-strand break repair.

Authors:  Hongjian Gong; Yuxi Zhang; Kunpeng Jiang; Shengfan Ye; Shuming Chen; Qinghe Zhang; Jinrong Peng; Jun Chen
Journal:  Cell Death Differ       Date:  2018-03-06       Impact factor: 15.828

7.  High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma.

Authors:  Katharina Bischof; Stian Knappskog; Ingunn Stefansson; Emmet Martin McCormack; Jone Trovik; Henrica Maria Johanna Werner; Kathrine Woie; Bjorn Tore Gjertsen; Line Bjorge
Journal:  BMC Cancer       Date:  2018-06-25       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.